table network network 2
demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only observational study
COVID 19 hospitalized
COVID 19 all comers
anti-inflammatoty and immuno-therapy
Immunostimulants drugs
convalescent plasma treatment LIFESAVER
interferon Cai -FAVIPIRAVIR Cai -FAVIPIRAVIR
neutralizing antibody
cilgavimab and tixagevimab (Evusheld) Chen
Immunosuppressants drugs
anti-interleukin-6
sarilumab
sarilumab high dose (400mg) sarilumab phase 2 high dose
sarilumab low dose (200mg) sarimulab phase 2 low dose
tocilizumab TOCOVID BACC Bay Tocilizumab Trial
janus kinase (JAK) inhibitor
baricitinib RECOVERY
leflunomide Wang

3 studies excluded by filtering options 2

4930 Huijie Bian, 2020 2313excludednot a RCThigh risk of bias
5612 Bernaola, 2020 2130excludednot a RCTrisk of bias not avaialble
8158 Yildiz, 2021 210excludedrisk of bias not avaialble

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons